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1 
Abstract 
Iron has outstanding biological importance as it is required for a wide variety of essential 
cellular processes and, as such, is a vital nutrient. The element holds this central position by 
virtue of its facile redox chemistry and the high affinity of both redox states (iron II and iron 
III) for oxygen. These same properties also render iron toxic when its redox-active chelatable 
‘labile’ form exceeds the normal binding capacity of the cell. Indeed in contrast to iron bound 
to proteins, the intracellular labile iron (LI) can be potentially toxic especially in the presence 
of reactive oxygen species (ROS), as it can lead to catalytic formation of oxygen-derived free 
radicals such as hydroxyl radical that ultimately overwhelm the cellular antioxidant defense 
mechanisms and lead to cell damage. While intracellular iron homeostasis and body iron 
balance are tightly regulated to minimise the presence of potentially toxic LI, under 
conditions of oxidative stress and certain pathologies, iron homeostasis is severely altered. 
This alteration manifests itself in several ways, one of which is an increase in the intracellular 
level of potentially harmful LI. For example acute exposure of skin cells to ultraviolet A 
(UVA, 320-400 nm), the oxidising component of sunlight provokes an immediate increase in 
the available pool of intracellular LI that appears to play a key role in the increased 
susceptibility of skin cells to UVA-mediated oxidative membrane damage and necrotic cell 
death. The main purpose of this overview is to bring together some of the new findings 
related to intracellular LI distribution and trafficking under physiological and patho-
physiological conditions as well as to discuss mechanisms and consequences of oxidant-
induced alterations in the intracellular pool of LI, as exemplified by UVA radiation. 
Key words: Iron, labile iron pool, oxidative stress, reactive oxygen species, skin, UVA 
2 
1 Introduction 
1.1 Iron and Oxidative Stress 
Iron is the second most abundant metal, after aluminium, and the fourth most abundant 
element in the earth’s crust (5%). Living organisms from bacteria to mammals use iron for 
1 
vital biological processes, as part of, or as a cofactor of proteins and enzymes. Iron plays a 
key role in mammalian cells’ growth, respiration and replication. Many iron-containing 
proteins catalyze key reactions involved in energy metabolism (cytochromes, mitochondrial 
aconitase, iron-sulfur proteins of the electron transport chain), respiration (e.g. hemoglobin), 
and DNA synthesis (i.e. ribonucleotide reductase) and it is well known that iron depletion 
2
leads to G1/S cell cycle arrest and apoptosis. Additionally, iron-containing proteins are 
3 
required for the metabolism of collagen, tyrosine and catecholamines.
Iron is a transition metal that can exist in two stable configurations: electron donor 
2+ 3+
ferrous (Fe ) and electron acceptor ferric (Fe ). The easy access to two oxidation states 
allows iron to act as a catalyst in mammalian cellular pathways that involve redox 
mechanisms, however this same property makes iron toxic when its redox-active chelatable 
4
‘labile’ form exceeds the normal binding capacity of the organism. Indeed in contrast to iron 
bound to proteins, the intracellular labile iron (LI) can undergo redox cycling between its 
+2 +3 •-
most stable oxidation states Fe /Fe and react with ROS such as superoxide anion (O2 ) and 
hydrogen peroxide (H2O2) giving rise to hydroxyl radical (OH 
•
) via the Fenton reaction 
5
(equation 2) or via superoxide-driven Fenton chemistry (equation 3). Such reactive ROS are 
capable of interacting with most biomolecules, depending on the site of bound iron, including 
sugars, lipids, proteins, and nucleic acids. These interactions promote various harmful 
processes in cells including lipid peroxidation, protein oxidation, DNA/RNA oxidation and 
DNA lesions and ultimately overwhelm the cellular antioxidant defense mechanisms and lead 
to cell damage and death. 
•− 3+ 2+
O2 + Fe  → Fe + O2 (1) 
2+ • ­ 3+
H2O2 + Fe  → OH + OH + Fe (2) (Fenton reaction) 
•­ Iron • ­
Net: O2 + H2O2  →OH + OH + O2 (3) 
3 
1.2 UVA and Oxidative Stress 
At the cellular level, the interaction of solar ultraviolet (UV) radiation with biological 
material changes as a function of wavelength and requires the absorption of the radiation by 
biomolecules. The UVB (290-320 nm) region of sunlight overlaps with the DNA absorption 
spectrum and as a result, the direct absorption of UVB by cellular DNA causes DNA 
6
photodamage and mutagenesis. In contrast, the UVA (320-400 nm) region of sunlight is 
weakly absorbed by most biomolecules but is predominantly oxidative in nature, generating 
7
ROS via photochemical interactions with intracellular chromophores. The ROS generated by 
UVA are certainly involved in cytotoxicity, as it has been shown that UVA inactivation of 
8
mammalian cells is strongly oxygen-dependent. Furthermore there is evidence from in vitro 
•-
studies that UVA irradiation of macromolecules can cause the generation of H2O2 and O2 
•-
and that iron-catalyzed reduction of H2O2 by O2 can further generate the highly reactive 
OH 
•
.
9,10 
Studies in prokaryotic and eukaryotic cells indicate that ROS may also be generated 
in vivo by UVA irradiation.
7,9,11 
UVA may also trigger the formation of ROS long after UVA 
exposure via non-photosensitised mechanisms. This may occur by activation of enzymatic 
•- 12 
systems such as NADPH oxidase that generates O2 . Based on such considerations, the 
UVA component of sunlight is now considered as a generator of intracellular oxidative stress. 
The uncontrolled production of ROS by UVA is undesirable and thus a number of 
protective strategies are adopted by cells to prevent their formation. Mammalian cells possess 
several antioxidant enzymes including superoxide dismutase (SOD), catalase and glutathione 
peroxidase (GPx). In addition, tissues contain many antioxidant molecules such as the 
endogenous compound glutathione (GSH), which is a major contributor to cellular reducing 
equivalents and compounds derived from the diet such as vitamins (e.g. alpha-tocopherol, 
ascorbate), carotenoids and flavonoids. It has been shown that GSH plays a critical role in 
13 
cellular defence against the lethal action of both UVA and UVB radiations. All these 
antioxidant enzymes and molecules would be expected to be important in cellular defence 
against UVA-induced oxidative stress. However the release of LI in skin cells that occurs 
14 
immediately after UVA irradiation provokes the excess production of highly reactive ROS 
such as OH 
• 
which can overwhelm the antioxidant capacity of the cells leading to cell 
damage and possible death (see sections 1.3 and 2.3). 
4 
1.3 UVA, Iron and Oxidative Stress 
Under normal conditions, iron levels in cells and body are under extremely tight control and 
there is little opportunity for iron-catalysed free radical generating reactions to occur. 
However upon exposure to oxidising agents such as UVA, the intracellular iron status 
changes dramatically as UVA leads to both LI and free heme releases in cells.
14,15 
Although 
heme itself is not a source of LI, it is a substrate for heme-catabolising enzyme heme 
oxygenase (HO) which could release the heme iron and expand the pool of potentially 
16 
harmful cytosolic LI. The dual role of UVA as ROS generator and LI enhancer classifies 
this radiation as a potent oxidising component of sunlight. Indeed UVA-mediated generation 
of ROS not only induces direct oxidative damage to skin constituents but also leads to an 
immediate increase in cytosolic labile iron pool (LIP) which in turn exacerbates the oxidative 
1
damage already occurring in the skin cells. Both singlet oxygen ( O2) and H2O2, the most 
important ROS species generated by UVA, exert their biological damage in skin cells 
17-20 
predominantly via iron-catalysed oxidative reactions. For example it has been shown that 
physiologically relevant doses of UVA induce lipid peroxidation in membranes of human 
primary fibroblasts and keratinocytes via pathways involving iron, H2O2 and 
1
O2.
17,21,22 
In 
fact lipid peroxidation that is considered as the prominent marker of UVA-induced photo-
oxidative damage in skin involves iron as the major contributor for initiation and propagation 
of peroxidative damage.
17,21-23 
This is because iron ‘at’ or ‘near’ strategic targets such as cell 
membranes, can undergo redox cycling by reacting sequentially with one electron reductants 
and oxidants, thereby generating toxic oxidants such as OH 
• 
and lipid derived alkoxyl and 
peroxyl radicals and can elicit biological damage.
5,24 
Lipid peroxidation results in the 
destruction of membrane function and structure, disturbed membrane fluidity and ultimately 
25 
loss of membrane integrity and cell lysis.
The UVA-induced expansion of intracellular LIP ultimately overwhelms the cellular 
26 
antioxidant defense mechanisms and leads to cell damage. Depending on the severity of the 
UVA dose applied, the LI-mediated oxidative damage may lead to cell death by apoptosis or 
necrosis.
27,28 
Alternatively the damage may be processed in such way that the carcinogenesis 
26 
process is initiated or promoted. The injurious consequences of iron-catalysed damage 
exerted by UVA have been shown to play a key role in skin photoaging and the promotion of 
skin cancer.
23,26,28,29 
The understanding of the mechanisms underlying the disturbance of iron homeostasis 
by UVA appears therefore crucial to understand how UVA interacts with cells and tissues. 
5 
Here we first provide an overview of iron distribution in cells and body and then introduce 
the iron homeostasis machinery composed of a complex network of transporters, storage 
molecules and regulators that coordinately govern iron absorption, iron recycling, and the 
mobilisation of stored iron in the organism. While these regulatory networks minimise the 
pool of potentially toxic LIP in cells and tissues, we describe how iron homeostasis is altered 
under oxidative and pathological conditions. Using this knowledge, we then discuss the 
mechanisms and consequences of oxidant-induced alterations in the intracellular pool of LI, 
as exemplified by UVA radiation. 
2 Iron Absorption, Storage, Transport and Distribution 
2.1 The Body Iron Pool 
Iron is absorbed from the mammalian gastrointestinal tract by two protein-mediated 
2+ 30 
mechanisms, one absorbing iron as Fe and the other iron as heme. Primates have evolved 
not to be able to excrete iron, and therefore body iron levels are totally controlled by the 
31 
absorption process. The total amount of iron in an average human body is about 4-5 g, the 
majority (i.e. 75%) of which is incorporated into the heme complex and can be found in 
32 
proteins such as hemoglobin and myoglobin. Only a very small amount of the total body 
iron is present as an essential component of a very large number of heme (e.g. cytochromes, 
catalase, oxidases and peroxidases) and non-heme proteins and enzymes (e.g. ribonucleotide 
reductase and iron-sulfur proteins). All of these may account for no more than 10% of the 
total body iron pool. The remaining 15% can be found principally in the cytoplasm in the 
form of the iron storage protein ferritin (Ft) but also in lysosomes, as hemosiderin. 
Storage iron is found in the liver, mainly in the hepatocytes, but it is also found in 
macrophages in the liver, bone marrow, spleen and muscles, where it is readily available as a 
reserve in case of blood loss.
33,34 
Due to epithelial shedding in the gastrointestinal tract and 
the skin and because of blood loss in women, there is an average daily loss of 1-2 mg. This 
loss is usually compensated for by the absorption of iron through the diet which contains 
approximately 10-20 mg of iron of which 1-2 mg is absorbed under normal circumstances. 
This absorption is increased several-fold when iron levels are low (e.g. in anaemia and 
hypoxia) and decreased when the iron stores are replete (e.g. in iron-overload conditions and 
inflammation).
31,35 
6 
2.2 The Labile Iron Pool 
All the iron-complexing molecules leave body fluids and cells with an extremely low 
concentration of free transit iron. Nevertheless there is now strong evidence for the existence 
of a transit pool of catalytically active iron complexes which is distinct from intracellular iron 
associated with proteins and is known as the labile iron pool (LIP). Iron belonging to this 
pool is considered to be in steady-state equilibrium, loosely bound to low-molecular-weight 
36 
compounds, accessible to permeant chelators and metabolically and catalytically reactive.
The LIP has been detected both in the systemic circulation and inside cells and is likely that 
all daily uptake of the dietary iron (1-2 mg) will pass via the LIP stage before it is sequestered 
37 
by target proteins.
The LIP is associated with important functions: (a) physiologically, as readily 
available source of iron for incorporation into proteins; (b) pharmacologically, as target for 
chelators or metal scavengers; and (c) toxicologically, as vehicle for promoting the formation 
38 
of free radicals.
2.2.1 The Intracellular Labile Iron Pool. The continuous demand of iron for 
cellular function is thought to force a permanent flux of LI from the extracellular milieu to 
the cytoplasm. The cellular LIP in quiescent conditions comprises only minor fractions of the 
4
total cellular iron (i.e. less than 5%). Cabantchik and co-workers have defined the 
intracellular LIP operationally as a cell chelatable pool that comprises both ionic forms of 
2+ 3+
iron (Fe and Fe ) associated with a diverse population of ligands such as organic anions 
(phosphates and carboxylates), polypeptides, and surface components of membranes (e.g. 
phospholipid head groups).
4,37 
This definition implies that LIP can not only potentially 
participate in redox cycling but also be scavenged by permeant chelators. The latter property 
forms the basis for the quantification of the cellular LIP. 
4,37 
2.2.2 The extracellular Labile Iron Pool. In contrast to intracellular LIP, the 
presence of extracellular LIP is often associated with pathological conditions. The 
extracellular LIP (also called labile plasma iron) has been originally observed in iron 
overload β-thalassemia patients whose plasma transferrin (Tf) iron-binding capacity has been 
39 
exceeded. Further to β-thalassemia, other conditions of iron imbalance have been defined 
7 
(i.e. hemochromatosis), in which the extracellular LIP has been found to be bound to ligands 
other than Tf as non-Tf-bound iron. 
2.3 Iron Homeostasis 
To minimise damage caused by LI, both plasma and intracellular LIP are tightly regulated by 
means of a complex network of transporters, storage molecules and regulators that 
coordinately govern iron absorption, iron recycling, and the mobilisation of stored iron. 
These regulatory networks maintain an adequate level of iron for vital cell, tissue and organ 
functions, while also minimising the pool of potentially toxic LIP. 
The protein central for systemic iron homeostasis is the hepatic peptide hormone 
hepcidin that regulates plasma iron concentrations and tissue iron distribution by inhibiting 
dietary iron absorption and mobilization. Hepcidin acts by controlling the number of iron 
40 
channels through which cellular iron is delivered into plasma. In the small intestine, iron is 
transported out of the enterocyte into the blood via the basolateral iron export protein, 
ferroportin-1 (FP1).
41,42 
When plasma iron is in excess, hepcidin binds to FP1 receptor. This 
leads to internalisation and degradation of the FP1 receptor which in turn cause the blockage 
40 
of iron efflux into plasma, resulting in iron retention within cells. Hepcidin follows an 
inverse relationship with body iron levels: low levels can potentially cause iron overload, 
whilst high levels cause anaemia.
35,40 
In turn, hepcidin concentration is regulated by a variety 
of influences. Iron loading increases hepcidin production (to block further iron absorption 
and maintain homeostasis), and so does inflammation (to decrease extracellular iron 
43 
concentration and its accessibility to micro-organisms).
Alterations in intracellular LIP are normally sensed by the cytosolic iron regulatory 
proteins 1 and 2 (IRPs) which function as post-transcriptional regulators of both iron uptake 
via the transferrin receptor 1 (TfR1) and iron sequestration by the iron storage protein, Ft. 
This regulation occurs via binding of IRPs to conserved iron responsive elements (IRE) in the 
44 
untranslated region of Ft and TfR1 mRNAs. When iron is scarce in the LIP, Ft and TfR1 
mRNAs are specifically recognized and bound by the active forms of IRPs, leading to 
stabilisation of the TfR1 mRNA and inhibition of Ft translation, both of which will lead to 
enhanced levels of LIP. Conversely, during an increase in iron supply, IRPs are converted to 
low affinity mRNA-binding proteins, leading to the induction of Ft mRNA translation and the 
44 
degradation of TfR1 mRNA, which will ultimately lead to a reduction in the LIP.
8 
Iron regulatory protein 1 (IRP1) is the cytoplasmic counterpart of mitochondrial 
aconitase, the enzyme which converts citrate to isocitrate through a cis-aconitate intermediate 
1
in the tricarboxylic acid cycle by virtue of a catalytic iron-sulfur cluster. In iron-replete cells 
the cluster is assembled and IRP1 displays aconitase activity; in iron-depleted cells the cluster 
is lacking and IRP1 functions as an mRNA-binding protein. This reversible switch between a 
cluster-containing holoprotein and a cluster-deficient apoprotein therefore allows 
aconitase/IRP1 to constantly sense LI levels and to adapt them to cell requirements. Iron 
regulatory protein 2 (IRP2) is highly homologous to IRP1 but lacks aconitase activity, 
probably because of its inability to assemble an iron-sulfur cluster; the protein accumulates in 
1
iron-deficient cells and is rapidly targeted for proteasomal degradation in iron-replete cells.
44 
Unlike IRP1, IRP2 has a characteristic pattern of tissue expression and is also more 
1
sensitive to variations of iron in the diet. Moreover, when abundantly or uniquely expressed, 
1
it can act as the major or only modulator of intracellular iron metabolism.
2.3.1 Iron Homeostasis and Pathologies. Disruption of iron homeostasis in cells 
and body causes a severe unbalance in the availability of potentially harmful LI leading to a 
variety of disorders associated with iron-deficiency or -overload.
40,45,46 
Iron-overload 
conditions may occur either locally as in ischemic tissue or systemically as with genetic 
hemochromatosis or transfusion-induced iron overload. In such circumstances elevated levels 
47 
of LI ultimately lead to free radical-mediated tissue/organ damage.
The involvement of H2O2 in numerous types of cell and tissue injury is well-
48-51 
documented. Although H2O2 itself has low reactivity towards cell constituents, it is 
capable of forming highly reactive ROS in the presence of trace amounts of catalytic LI via 
Fenton reaction. Under physiological conditions, cells protect themselves either by the H2O2 
52 
–degrading enzymes catalase and GPx, or by minimising the intracellular level of 
potentially harmful LIP via the cytosolic IRP1 and IRP2 regulatory network.
44,53 
However 
under pathological conditions, these conventional cellular defences are often insufficient, 
because the system is either overwhelmed by an increased H2O2 formation
49,54-56 
and/or by an 
57 
excess presence of LI. The simultaneous presence of excess redox active chelatable LI and 
H2O2 can be potentially toxic for cells as it can catalyse the formation of oxygen free radicals 
such as OH 
• 
and can elicit irreversible oxidative damage. The pathological consequences of 
iron-catalyzed oxidative damage are recognized in diseases such as hepatitis, liver cirrhosis, 
58-
hemochromatosis, cancer, chronic inflammatory disorders and neurodegenerative diseases.
9 
66 
Excess iron may also aggravate diabetes, cancer, cardiovascular disease and alcoholic and 
67-71 
non-alcoholic steatohepatitis.
High levels of LI have also been identified as a risk factor for the development of 
72 
cancer. Numerous studies across a variety of populations have found a positive correlation 
between iron stores in the body and risk of the development of a range of cancers including 
73 
colorectal, liver, kidney, lung and stomach cancers. High dietary iron has also been reported 
74 
to induce skin cancer in mice. Furthermore in both animals and humans, primary neoplasms 
develop at body sites of large iron deposits such as skin, which is a potential target for 
significant oxidative damage due to its constant exposure to high oxygen tensions and 
32 
frequent exposure to ultraviolet (UV) light. During the process of carcinogenesis, 
intracellular iron homeostasis is altered, with neoplastic cells, poor in iron relative to their 
normal counterparts, internalizing iron from Tf at a tremendous rate, despite low levels of the 
2
iron storage protein, Ft.
The presence of excess iron has also been demonstrated in a variety of skin disorders 
75 76 77 
such as psoriasis, venous ulceration and atopic eczema, indicating the involvement of 
iron in the pathology of skin. 
Iron accumulation in the body also occurs with age in males. In women however, iron 
accumulation does not occur until after the menopause. Iron accumulation in post-
78 
menopausal women has been linked to increased incidence of heart disease. Increased 
levels of iron in post-menopausal women have also recently been considered as etiological 
79 
agents potentially involved in the increased risk of oxidative damage in skin. There is also 
evidence for age-related accumulation of LIP associated with rheumatoid arthritis, 
68 
atherosclerosis and Alzheimer’s disease (AD). Interaction of iron and cholesterol in 
promoting oxidative damage has been suggested as causative of both atherosclerosis and 
80 
neurodegeneration. Mutations in genes involved in controlling iron have also been shown to 
68 
cause predisposition to AD. Iron may also play a role in the carcinogenic process of other 
72 
transition metals such as copper, or other types of carcinogens.
2.3.2 Iron Homeostasis and Oxidative Stress. In addition to pathological 
conditions, iron homeostasis can also be severely altered under oxidative stress conditions. 
For example, IRP1 is susceptible to oxidative inactivation of RNA binding in vitro and in 
vivo.
81,82 
By contrast, menadione, nitric oxide, and H2O2 activate IRP1 RNA-binding activity 
10 
and, as a result, lead to a coordinated decrease of Ft synthesis and induction of TfR1 
expression.
83,84 
On the other hand, Cairo et al have observed that in cell-free systems, H2O2 
•-
cannot directly modify IRP1 but instead can cooperate with O2 and down-regulate IRP1 
85 
activity. The authors have further demonstrated that down-regulation of IRP1 occurs also in 
vivo in liver tissue of rats subjected to ischemia reperfusion or phorone, a GSH-depleting 
57,86 
agent.
We have also observed that exposure of skin cells to UVA (320-400 nm) inactivated 
14 
the mRNA-binding activity of IRP1 and that this correlated with a reciprocal increase in the 
aconitase activity of the IRP-1 (which is known to occur in response to the increased 
availability of intracellular LIP
1
).
. 
The inactivation of IRP1 by UVA in skin fibroblasts is 
related to the excess LI and this was confirmed by measuring the LIP levels with the 
36 
fluorescent Calcein assay. From these observations, it was concluded that UVA induces 
14 
immediate release of LI in the skin fibroblast cells. Further studies from this laboratory 
revealed that in addition to UVA, H2O2 treatment of skin fibroblasts also promotes a dose-
dependent increase in intracellular LIP.
26,87,88 
Furthermore our investigations revealed that the 
proteolytic degradation of Ft by UVA is a major contributor to the observed increase in LI in 
14 
irradiated skin fibroblasts. Numerous other studies have also demonstrated that pro-oxidant 
stresses are capable of modulating iron homeostasis by elevating the intracellular LIP via 
release of iron from sensitive sites, such as iron-sulfur clusters and Ft. Stress stimuli for 
which this has been observed include peroxides, nitrofurantoin, nitric oxide, phorone, 
ischemia-reperfusion and hypothermia injury.
14,26,37,57,86,89 
In addition to IRP1, IRP2 is also specifically modulated in response to oxidative stress 
1
in the form of enhanced production of ROS and reactive nitrogen intermediates.
Oxidative stress can also affect iron homeostasis via activation of heme oxygenase 1 
(HO-1). The strong transcriptional activation of HO-1 by UVA was first identified in human 
90 
skin fibroblasts. Later studies demonstrated that this phenomenon also occurs in 
melanocytic and dendritic cells, and in certain pathologic states it is detected in epidermal 
91 
keratinocytes. It is now recognised that all conditions that lead to perturbation of heme 
homeostasis (e.g. oxidative stress, tissue injury and inflammation) lead to rapid changes in 
heme synthesis (via aminolevulinate synthases) and catabolism (via HO). This adaptive 
response to restore heme homeostasis in oxidative stress and related pathological conditions 
must also take care of any perturbations in cellular LIP so that Ft is almost always induced, 
albeit more slowly, under the same conditions. The aberrant cellular and tissue iron 
11 
distribution and severe iron-deficient anemias observed in HO-deficient rodents (and in the 
one human case recognised to date) indicate that heme oxygenases themselves also play a 
92 
crucial role in controlling tissue iron distribution and homeostasis.
Studies from Tyrrell’s laboratory have shown that acute exposure to UVA or H2O2 
promotes immediate heme release from microsomal hemoproteins in a human primary skin 
15 
fibroblasts cell line, FEK4. Although heme itself is not a source of LIP, it is a substrate for 
the heme-catabolizing enzyme, HO which could release the heme iron. In the short term, HO 
activity can cause hypersensitivity to oxidative UVA radiation due to release of iron from 
93 
heme. In the long term (i.e. 1-2 days) however, the UVA-mediated activation of HO-1 leads 
94 
to HO-1-dependent increase in Ft and a consequent lowering of the pro-oxidant state in skin 
95 
cells. Studies from Girotti and co-workers have also shown that short-term treatment of 
murine lymphocytic leukemic cells with hemin, causes an early increase in HO-1 and LI that 
sensitises the cells to acute oxidative killing, however long-term hemin treatment results in 
elevated H-Ft levels that sequesters the potentially harmful LI and enhances cellular 
96 
resistance to acute exposure to oxidants. In contrast to acute conditions, repeated exposure 
of cells to oxidizing agents such as UVA or H2O2 has been shown to induce the HO-1 
refractory response presumably as a safety mechanism to shut off the excess LI production as 
a result of repeated heme breakdown.
16,97-99 
Recent research aimed at understanding the mechanisms underlying the oxidant-
induced alterations in iron homeostasis has revealed that the differential subcellular LI 
distribution plays a key role in promotion of iron-catalysed oxidative damage in cells. 
Furthermore translocation and trafficking of LI between subcellular compartments appears to 
be a hallmark of oxidative stress leading to propagation of iron-catalysed oxidative damage in 
cells. In order to understand the consequences of alteration of iron homeostasis by UVA, it is 
therefore necessary to understand how LI is distributed in subcellular compartments under 
physiological and oxidative conditions. The following sections provide an overview of the 
recent findings in this domain. 
2.4 Labile Iron Distribution in Subcellular Compartments 
Due to the high physiological and patho-physiological importance of LI distribution, great 
efforts have been made to develop suitable methods to investigate the intra- and sub-cellular 
LI levels. Most methods to characterize intracellular LI distribution seriously perturb the 
12 
100 
extent and nature of the LIP, rendering them inapplicable to living cells. In combination 
with non-invasive and high resolution confocal imaging, fluorescent chemosensors have 
proven to be highly sensitive tools to investigate the metabolism of LIP in individual cells 
with subcellular resolution. The methodology developed by Cabantchik and co-workers using 
Calcein-AM, a fluorescein derivative has so far been the most frequently applied fluorescent 
4
chemosensor to study intracellular LIP. However, due to hydrophilic nature of Calcein (CA) 
and lack of access to subcellular compartments, it has been demonstrated that the CA-based 
101 
measurements reflect mostly the cytosolic LI rather than the overall intracellular LIP.
Using this methodology, we observed that the cytosolic LIP levels of primary human skin 
28 
keratinocytes were 2-3 fold lower than their matched primary human skin fibroblasts. The 
lower cytosolic LI content of skin keratinocytes correlated with their higher resistance to 
28 
UVA-induced oxidative damage. Interestingly CA-assay also revealed that the cytosolic LIP 
content of highly proliferative human keratinocytes is much higher (i.e. 3-4 fold) than the low 
proliferating primary skin keratinocytes, as observed in a series of squameous cell carcinoma 
and psoriatic cell lines isolated from patients (unpublished data, this laboratory). The high 
requirement of neoplastic cells for iron that is required for rapid cell division has been shown 
to provoke an adaptive cellular response in the form of high Tf-bound iron uptake by 
increased TfR1 expression and low iron storage by decreased Ft content to maximise the 
availability of intracellular LIP for ribonucleotide reductase that requires iron for DNA 
2
synthesis.
To overcome the limitation of the CA-fluorescent assay, Hider and co-workers have 
recently developed a range of highly sensitive novel fluorescent iron chelators such that a 
fluorescent function (i.e. coumarin substitutes) is covalently linked to 3-hydroxypyridin-4-
one (HPO). Among these, CP655 (7-diethylamino-N-[(5-hydroxy-6-methyl-4-oxo-1,4-
dihydropyridin-3-yl)methyl]-N-methyl-2-oxo-2H-chromen-3-carboxamide), which is a 
moderately lipophilic fluorescent chelator, was found to be the most sensitive probe for 
monitoring intracellular LIP.
102,103 
The concentration of the intracellular chelatable iron pool 
103 
in hepatocytes was determined by this probe to be 5.4+/-1.3 micromolar. 
To measure the distribution of LI in subcellular compartments, Petrat and co-workers 
introduced a fluorescein-based iron sensor ‘Phen green SK’ incorporating a 1,10-
Phenanthrolin chelation unit.
104,105 
This iron sensor was capable of detecting much higher 
cytosolic LI concentrations in cultured hepatocytes as well as being able to detect LI in 
subcellular compartments in a number of cultured cell lines. The quantitative studies of 
13 
chelatable LI with ‘Phen green SK’ revealed that both lysosomal and mitochondrial 
105-107 
compartments have 2-3 fold higher levels of LI when compared to the cytosolic pool.
These studies also highlighted the surprisingly high content of redox-active LI in the nucleus 
37 
with clear implications for an increased probability of DNA damage.
The presence of high levels of LI in mitochondria, lysosomes and nucleus makes 
these organelles highly vulnerable to oxidative damage upon exposure to oxidising agents 
26 
such as UVA or H2O2. For example we have observed that in skin fibroblasts, UVA 
promotes an immediate and dose-dependent damage to lysosomal, mitochondrial and nuclear 
membranes that can be prevented by organelle-permeable iron chelator pre-
14,26,28,87,88,108 
treatment.
The development of real-time fluorimetry and flow cytometry techniques in 
conjunction with targeted fluorescent iron sensors capable of monitoring concurrently the 
109 
cytosolic and mitochondrial LI changes as well as lysosomal/endosomal-specific 
fluorescent iron sensors with high responsiveness towards alterations of 
100 
endosomal/lysosomal LI have provided valuable insights into understating the mechanisms 
underlying the subcellular LI distribution and trafficking under physiological and patho-
physiological conditions. Below, we provide a summary of the recent findings in this domain. 
2.4.1 Cytosolic LIP. The main source of cytosolic LIP is via Tf-TfR1-mediated 
110 
endocytosis (see Fig. 1). Cells which require iron express the TfR1 on their surface, which 
+3 -23 
binds two molecules of Tf. Transferrin has a high affinity for Fe (Kd= 10 mol/L) and its 
primary function is to accept iron from plasma (which then takes on the diferric form) and to 
transport iron into various cells and tissues, by binding to TfR1. The Tf-TfR1 complex is then 
internalized by receptor-mediated endocytosis, where the diferric Tf-TfR1 complex is taken 
into the cell.
60, 111 
Once in the endosome, the pH decreases via a proton pump present on the 
3+ 
endosomal membrane allowing the Fe ions to dissociate from the Tf-TfR1 complex. The 
endosomal ferrireductase ‘Steap3’ (six-transmembrane epithelial antigen of the prostate-3),
3+ 2+ 2+ 
is thought to convert Fe to Fe in the endosomes, allowing Fe ions to be transported out of 
113 2+ 
the endosomes by divalent metal transport protein, DMT1. Once in the cell, Fe ions are 
thought to enter the cytosolic LIP. A recent study by Cabantchik and co-workers using live 
and real-time fluorescence techniques has revealed that in K562 human erythroleukaemia 
cells, most of Tf-bound iron is indeed delivered to the cytosolic LIP by a saturable 
14 
112 
mechanism that is quantitatively dependent on TfR1 levels, endosomal 
acidification/reduction for dislodging iron from Tf and the ensuing translocation of LI into 
109 
the cytosolic compartment.
The endosomes containing the Tf–TfR1 complex then undergo exocytosis to recycle 
TfR1 and return the apo-Tf to the bloodstream where it is able to bind more iron from the 
114 
liver (see Fig. 1).
The cytosolic LIP can reach several targets (see Fig. 1). It can either be stored in Ft 
115 
for long term storage or be readily used in the synthesis of various proteins and enzymes 
116 
such as ribonucleotide reductase. In general it is assumed that most of the cytosolic LI that 
is not metabolised is stored in Ft. Ferritin is an ubiquitously expressed cytosolic iron storage 
protein which forms a hetero-oligomeric protein shell composed of 24 Ft light (L-Ft, 19kD) 
and heavy (H-Ft, 21kD) chain subunits. Up to 4500 iron atoms can be sequestered in Ft as a 
3+
crystalline core of ferric ions (Fe ). Storing iron in Ft prevents LI from generating toxic 
115 
radicals and allows the regulated release of iron. Studies with murine and rat models have 
shown that loss of cytosolic iron storage Ft by down-regulating or deleting H-Ft leads to an 
increase in LIP, oxidative stress, tissue damage and cell death.
117,118 
Recent work has 
identified a cytosolic iron chaperone, PCBP1 [poly (rC)-binding protein 1] that transports 
119 
iron to Ft. Depletion of PCBP1 in human cells inhibited Ft iron loading and increased 
119 
cytosolic LIP.
The cytosolic LIP may also reach the mitochondria directly via the putative 
mitochondrial iron import protein, mitoferrin (Mf), for synthesis of heme and iron-sulfur 
110 2+ 
clusters. The latter pathway was first supported by Lange et al who measured Fe ingress 
120 
into isolated mitochondria. The recent development of real-time fluorimetry and flow 
cytometry techniques in conjunction with targeted fluorescent iron sensors capable of 
monitoring concurrently the cytosolic and mitochondrial changes in LI evoked by Tf-bound 
109 120 
iron confirmed the initial observation by Lange et al. Using this methodology, 
Cabantchik and co-workers demonstrated that the bulk of Tf-bound iron initially delivered to 
cells via endocytosis can be quantitatively traced in the cytosol as cytosolic LIP, from where 
109 
it is distributed to other cell compartments, notably mitochondria. At present it is not 
known whether cytosolic LI is delivered to mitochondria by high-affinity chaperone-like 
moieties, as proposed for Ft or simply by diffusion.
109,110,119 
The mitochondrial protein 
frataxin, that is deficient in individuals suffering from neuromuscular disease Friedreich’s 
ataxia (FRDA), could conceivably fulfil the chaperone-like function, as frataxin is thought to 
15 
deliver iron for the synthesis of iron- sulfur clusters to these organelles and has also been 
110 
recently found in the cytosol. The presence of a high-affinity chaperone-type iron 
acquisition system to mitochondria is also supported by a study by Garrick et al, who 
121 
demonstrated that high affinity iron chelates could donate iron for heme synthesis.
It has been proposed that iron delivery to mitochondria may also occur via an 
alternative mechanism that bypasses the cytosolic LIP route. This includes the direct transfer 
of iron from endosomes (i.e. iron sequestered by Tf-TfR1 pathway) to the mitochondria as a 
‘kiss-and-run’ mechanism, mediated by DMT1 (as endosomal iron exporter) and Mf (as 
mitochondrial iron importer) (see Fig. 1).
122,123 
This alternative mechanism is thought to 
apply primarily to erythroid cells which require a high rate of iron utilization for heme 
122-125 2+ 
synthesis. The terminal step of heme biosynthesis requires the insertion of Fe ion by 
ferrochelatase enzyme into heme precursor, protoporphyrin IX (PPIX) to produce heme. In 
hemoglobin-synthesizing cells, the vast majority of iron released from endosomes must cross 
126 
both the outer and the inner mitochondrial membranes to reach ferrochelatase. It is 
remarkable that in these cells iron acquired from Tf continues to flow into mitochondria, even 
127-129 
when the synthesis of PPIX is markedly compromised in vitro (by isonicotinic acid 
130 
hydrazide or succinylacetone) or in vivo (patients with erythroid specific 5-aminolevulinate 
synthase deficiency). A significant proportion of non-heme iron that accumulates in 
mitochondria under these circumstances is in a form readily available for heme synthesis 
127-129 
when PPIX formation is restored. The ‘kiss-and-run’ is defined as a transient endosome-
mitochondrion interaction to mediate iron transfer between these organelles. This model 
proposes that, after iron is released from Tf in the endosome, it is passed directly from 
endosomal iron exporter DMT1 to mitochondrial iron importer Mf until it reaches the 
ferrochelatase in the mitochondrion. Interestingly, when heme synthesis is inhibited in 
definitive erythroid cells, very little
128,129 
or no 
131 
iron accumulates in cytosolic Ft. In 
contrast, it is well established that in normal non-erythroid cells, iron in excess of metabolic 
needs ends up in Ft. Thus, it seems highly likely that in erythroid cells the transport of iron 
into mitochondria is controlled differently than in non-erythroid cells.
122,126 
Metabolites can cross the mitochondrial outer membrane through a large diameter 
132 
voltage dependent channel, also known as mitochondrial porin, while the inner 
mitochondrial barrier can only be crossed with the aid of specialised mitochondrial solute 
133 
carrier family (MCF), localised in the inner mitochondrial membrane. Mitoferrin-1 (Mf1, 
Slc25a37), is a member of the MCF that functions as an essential iron importer for the 
16 
124 
synthesis of heme and iron-sulfur clusters in erythroblasts. Recent work has shown that in 
erythroblasts, ferrochelatase forms an oligomeric complex with Mf1 and Abcb10 to 
125 
synergistically integrate mitochondrial iron incorporation and use for heme biosynthesis. A 
similar protein, named mitoferrin-2 (Mf2) has also been identified in Zebrafish and mammals 
134 
that unlike erythroid Mf1, is expressed at low levels in all tissues. The latter may be 
133 
involved in iron import into the mitochondria of non-erythroid cells. In skin fibroblasts, we 
have observed that growing cells under low serum concentration for several days could 
substantially decrease the basal intracellular level of LIP (as measured by IRP1 RNA-binding 
activity) and cause a related increase in the basal level concentrations of the mitochondrial 
heme precursor PPIX. The latter study suggests that the extent of heme biosynthesis in 
135 
mitochondria of skin cells is directly related to the availability of intracellular LIP.
Alternatively the cytosolic LIP may reach the plasma membrane where it is exported 
110 
via the iron exporter protein FP1 (see Fig. 1). The divalent iron exporter FP1 (also called 
136 
IREG1 and MPT1) has been found in the basolateral membrane of enterocytes. It has been 
shown that FP1 is only expressed in liver, spleen and kidney, so the mechanism of iron export 
37 
from other cell types is unclear.
2.4.2. Mitochondrial LIP. The majority of cellular iron is utilised in the 
137 
mitochondria for the biosynthesis of both heme and iron-sulfur clusters. This makes the 
138 
mitochondrion an important organelle in iron trafficking. The chemical form of available 
133 
iron inside the mitochondrion remains an elusive issue. Studies with improved fluorescent 
iron chemosensors such as Rhodamine B-based sensors selectively detected a form of 
139 
chelatable LI in the mitochondrial matrix of cultured rat hepatocytes and cardiomyocytes,
human erythroleukemia K562 cells
107,109 
and fibroblasts from FRDA patients.
140 
As 
mitochondria are the main cellular iron consumers, as well as being the principal source of 
O2·
-
, LI levels are kept to minimum via tight coordination of the rate of influx with the rate of 
incorporation into heme and iron-sulfur clusters.
110,133 
2.4.3 Lysosomal LIP. Autophagy appears to be the main process that delivers 
substrates to the lysosomal compartments in all cells except erythrocytes, which lack 
141 
lysosomes. The ongoing decomposition of iron-containing metalloproteins such as Ft and 
mitochondrial electron transport complexes within these acidic organelles is accompanied by 
17 
the release of redox-active LI. Studies by Petrat and co-workers suggest that the intra-
lysosomal pool of LI is a major source of intracellular LIP, being 2-3 fold higher than 
106 
cytosolic LIP. The presence of LI in lysosomes has also been confirmed by Hider and co-
workers who designed a series of HPO-based highly specific fluorescent probes that 
exclusively accumulate in lysosomal compartments and possess high responsiveness toward 
100 
alterations of lysosomal LIP.
Upon export from lysosomes, this rich source of LIP may contribute to the continued 
142-144 
synthesis of new iron-containing proteins, although it is not known exactly how redox-
active LI is transported from lysosomes to other subcellular compartments. The transport of 
lysosomal LI to cytosol may involve DMT1 similar to release of iron from late endosomes, 
141 
although it is not known whether iron bound to DMT1 is redox-active. An alternative 
mechanism for the delivery of LI from late endosomes/lysosomes to mitochondria may 
involve the direct transport between these two organelles following temporary close contact 
(see ‘kiss-and-run’ in section 2.4.1).
122,123 
2.4.4 Nuclear LIP. Petrat et al were the first to detect a source of LI in the nucleus 
105-107 
of a series of cultured cell lines. Cabantchik and co-workers further confirmed the 
presence of LI in nucleus of cardiac cells by means of a fluorescent LI sensor (i.e. CAL-G) 
145 
covalently attached to histones. This study also highlighted the existence of a dynamic and 
rapid equilibrium between the cytosolic and nuclear LI pools presumably via nuclear 
145 
pores. 
2.5 The Role of Subcellular LIP Distribution in the Cellular Response to Oxidative 
Stress 
Earlier studies aimed at understanding the role of intracellular LIP in potentiating oxidative 
damage in cells consisted of loading the cells with Tf-Fe or iron-salts followed by an 
oxidative challenge of cells with oxidizing agents such as t-butyl-hydroperoxide (TBHP), 
H2O2 or UVA radiation. These studies indicated that concomitantly with the rising of LIP 
levels in the cytosol (as measured by CA-assay), there was demonstrable rise in ROS 
production (possibly via Fenton reaction), lipid peroxidation and eventual cell death.
2,146,147 
Recent studies revealed however that the relationship between cytosolic LIP and intracellular 
ROS generation is more complex than previously thought. Indeed it is now known that 
18 
intracellular LIP can not only act as a potent generator of ROS but its level can also be raised 
by oxidants or reductants. 
2.5.1 The Role of Ft Iron in Oxidant­mediated Increase in Cytosolic LIP. The 
mechanism of iron release from Ft is still under investigation. Various reductants and 
chelators, including physiological and toxicological substances are capable of releasing iron 
37 
from Ft. It has been shown that under conditions of iron depletion (e.g. after iron chelation 
treatment) and in absence of extracellular iron resources, Ft iron can be directly released in 
148 
the cytosol via proteolysis to replenish the cytosolic LIP. Breuer et al studied the possible 
149 
alteration of intracellular LIP in K562 cells that were treated with TBHP or H2O2. The CA-
assay revealed that a short exposure to these oxidants can raise the cytosolic LIP in a dose-
149 149 
dependent manner. This phenomenon was attributed to reductive release of iron from Ft,
150-152 153 
as has been previously shown in vitro for superoxide radicals, sulfhydryl reagents and 
154-157 
other agents including UVA light.
Direct measurements of intracellular LIP by electron paramagnetic resonance also 
indicated an expansion in intracellular LI with a concomitant drop in intracellular Ft levels in 
the liver of rats subjected to oxidative stress in the form of phorone (a GSH-depleting drug) 
or ischemia-reperfusion.
57,86 
The early drop in Ft in the latter studies was demonstrated to be 
a proteolytic degradation event leading to an increase in intracellular LIP.
57,86 
Studies from 
this laboratory have also demonstrated that the UVA-induced increase in cytosolic LIP is 
14 
partly due to proteolytic degradation of Ft.
Ferritin degradation in cytosol may occur via proteasomes upon oxidative damage, 
pathological conditions, FP1 overexpression or treatment with oral iron chelators such as 
115 
deferiprone. However lysosomal proteases have also been shown to be involved in the 
oxidant-mediated degradation of Ft and the related increase in cytosolic LIP. Under 
physiological conditions, the predominant mechanism of iron release from Ft is through the 
constitutive degradation of the protein in lysosomes by specific lysosomal proteases, notably 
14 
chymotrypsin. The half-life of Ft in the cytosol is estimated to be 24-72h (depending on the 
cell type), after which it is transported into lysosomes where its iron is thought to be recycled 
for cellular requirements notably heme synthesis.
141,158 
The high turnover of both 
endocytosed and autophagocytosed iron-containing macromolecules (e.g. Ft and 
mitochondrial electron transport complexes) cause the accumulation of the potentially 
19 
hazardous LI in lysosomal compartments that render these organelles highly vulnerable to 
26 
oxidative damage upon exposure to oxidizing agents including UVA radiation. In skin 
fibroblasts, UVA has been shown to promote the proteolytic release of Ft iron in the cytosol. 
The UVA-induced proteolytic degradation of Ft occurs as a result of radiation-mediated 
14 
damage to lysosomal membranes leading to leakage of lysosomal proteases to the cytosol.
Pretreatment of skin fibroblasts with Leupeptin and Chymostatin (lysosomal protease 
inhibitors) prevented the UVA-induced Ft degradation and caused a substantial decrease in 
14 
the level of cytosolic LI released by UVA. We have also previously reported a clear link 
between the lower basal level of Ft and UVA-induced release of cytosolic LI in keratinocytes 
that may be in part responsible for the resistance of primary skin keratinocyte cells to UVA-
induced LI damage as compared to their UVA-sensitive matched primary skin fibroblasts that 
28 
contain higher basal Ft level and release more cytosolic LI upon UVA exposure.
So it appears that Ft iron can replenish the cytosolic LIP upon oxidative stress as it 
110 
can be released either reductively or as a result of its proteolytic degradation. Therefore Ft 
plays a dual role in LIP homeostasis, acting on the one hand as an iron-sequestering protein 
and on the other hand as a potential source of LIP.
26,37 
2.5.2. The Role of Lysosomal LIP and Proteases in Oxidant­mediated Cell 
Damage. The oxidant-mediated destabilization of lysosomal membranes and rapid leakage of 
both lysosomal LIP and proteases to the cytosol leads to a cascade of events resulting in cell 
death (i.e. apoptotic or necrotic cell death, depending on the extent of insult).
14,26,27,141 
The role of redox-active LI in compromising the stability of lysosomes under 
oxidative stress is well-demonstrated in studies involving simultaneous exposure of cells to 
an oxidising agent and a potent iron-specific chelator. For example Brunk and co-workers 
have reported that the combined treatment of cells with H2O2 and the highly lipophilic iron 
chelator salicaldehyde isonicotinoyl hydrazone (SIH) almost fully prevents both lysosomal 
rupture and cell death. The lack of oxidative effect of H2O2 in presence of SIH strongly 
suggests that H2O2 per se is not particularly toxic but rather must work in concert with iron in 
141 
order to damage cells. Similarly the pre-treatment of skin cells with lysosomotrophic 
strong iron chelator desferrioxamine (DFO) or the highly lipophilic iron chelator pyridoxal 
isonicotinoyl hydrazone (PIH) significantly protected the cells against UVA-mediated 
87 
lysosomal damage (unpublished data, this laboratory) and the ensuing necrotic cell death by 
20 
1 
virtue of their strong iron-chelating properties.
141,159,160 
It is noteworthy that H2O2 and O2 are 
recognised as the predominant intracellular ROS generated by UVA promoting biological 
17-20 
damage in exposed tissues via iron-catalysed oxidative reactions.
It has been suggested that the concomitant release of lysosomal proteases and LIP 
following oxidative damage and the consequent destabilisation of the lysosomal membranes 
might activate feedback processes that would cause further lysosomal rupture. Such feedback 
processes may be either LIP-mediated and/or due to activation of lytic cytosolic pro-enzymes 
such as caspases.
14,161,162 
Lysosomal proteases such as cathepsins B/L/D and chymotrypsin 
have been specifically detected in the cytosol of cells treated with oxidising agents, indicating 
their translocation from lysosomal compartments to the cytosol as a result of oxidative 
damage to lysosomal organelles.
14,27,161 
The level of chymotrypsin, the lysosomal protease 
responsible for the degradation of Ft, was found to increase in a dose-dependent manner in 
the cytosol of skin fibroblasts subjected to a series of doses of UVA at natural exposure 
14 
levels. The latter provided a rational explanation for the observed rapid proteolytic 
14 
degradation of Ft in the cytosol of skin cells subjected to UVA radiation. Iron loading of 
cells prior to UVA radiation exacerbated both the lysosomal damage (unpublished data, this 
28 
laboratory) and the ensuing cell death in skin cells.
Lysosomal organelle rupture resulting from intra-lysosomal Fenton-type reactions 
upon exposure to oxidative agents has also been associated with enhanced DNA damage due 
162 
to sudden release of lysosomal LI into the cytoplasm. It has also been suggested that 
permeabilization of mitochondrial membranes by release of lysosomal proteases may also 
induce a loss of mitochondrial membrane potential, irreversibly leading to cell death.
100,142,163 
The pre-treatment of cells with lysosomotrophic iron chelator DFO prevented the oxidant-
induced lysosomal membrane damage, DNA damage, loss of mitochondrial membrane 
potential and cell death,
26,164,165 
implying the important role of lysosomal LI in catalysing 
harmful oxidative damage. 
2.5.3 The Role of Heme iron in Oxidant­mediated Increase in Cytosolic LIP. In 
addition to Ft iron, heme iron may also contribute to the oxidant-mediated rise in cytosolic 
LIP. Studies from Tyrrell’s laboratory have shown that immediately after exposure of skin 
fibroblasts to UVA or H2O2, heme is released from microsomal hemoproteins to the 
15 
cytosol. Although heme itself is not a source of LIP, it is a substrate for heme-catabolising 
21 
enzyme HO which could release the heme iron and expand the pool of potentially harmful 
cytosolic LI. The role of heme iron in exacerbating the UVA-induced oxidative damage was 
well illustrated by Kvam et al who showed that overexpression of HO-2 in a Hela cell line 
could cause a transient hypersensitivity to UVA; this effect depended on release of iron from 
93 
heme. Hemin treatment was also found to strongly sensitise the skin keratinocytes to UVA-
28 
induced necrotic cell death. The latter study indicated a clear link between heme iron, Ft 
iron and the cytosolic LIP i.e. overnight hemin treatment induced a 4-fold increase in Ft 
levels that contributed to a 3-4 fold increase in cytosolic LIP in keratinocytes following UVA 
28 
radiation. These studies highlighted the pro-oxidant potential of Ft iron in exacerbating the 
UVA-induced oxidative damage, as its upregulation led to enhanced cellular damage and cell 
death. This is in stark contrast to studies showing that upregulation of Ft (i.e. by 
overexpression of H-Ft or hemin treatment), could reduce oxidative stress responses and 
protect the cells against H2O2-induced cyto- and geno-toxicity.
96,166,167 
The differential 
mechanism of LI-induced oxidative-damage induced by H2O2 and UVA may be the reason 
for this discrepancy. 
2.5.4 The Role of Mitochondrial LIP in Oxidant­mediated Cell Damage and 
Death. In addition to cytosolic and lysosomal LI, mitochondria have also been recognised as 
the principal destination of LI in cells and therefore a primary site of pro-oxidant generation 
rendering these organelles particularly susceptible to oxidative damage. Since mitochondria 
are the major sites of oxygen consumption and LI is also a potent inducer of ROS formation, 
the simultaneous presence of oxygen and iron appears to be detrimental to the organelles. 
Chelatable LI was detectable in the mitochondria of cultured hepatocytes and cardiomyocytes 
139 
with high affinity probes and with iron chelators capable of inhibiting mitochondrial ROS 
168 
generation. Although mitochondria have evolved mechanisms to regulate iron-dependent 
damage and maintain mitochondrial functionality, it appears that the organelles remain 
susceptible to oxidative damage and alterations in mitochondrial iron homeostasis ultimately 
lead to pathological phenotypes and cell death.
26,28 
The consequences of a pathological rise in mitochondrial LIP have been well 
documented in a series of genetic disorders with defective cellular iron utilization (i.e. 
trafficking and incorporation into proteins) whereby LI concentrations rise to toxic levels in 
mitochondria of excitable cells often leaving the cytosol iron-depleted. These inherited 
disorders include FRDA, myopathy with iron-sulfur cluster scaffold protein deficiency, X-
22 
170 
169 
linked sideroblastic anemias and neurodegeneration with brain iron accumulation. The 
studies in this field have highlighted a positive correlation between preferential accumulation 
of redox-active LI in mitochondria and oxidative damage in sensory neurons, the 
169 
myocardium and endocrine glands. Wong et al have also demonstrated that cultured 
fibroblasts from FRDA patients that contain high mitochondrial iron level are highly sensitive 
to iron stress and significantly more sensitive to H2O2-mediated cell death than controls.
In addition to its involvement in pathological conditions, mitochondrial LI level has 
also been recently identified as the key determinant of susceptibility of cells to oxidative 
stress. Studies from this laboratory have demonstrated that exposure of cultured human skin 
fibroblasts to UVA promotes immediate damage to mitochondrial membranes and that this 
28 
plays a key role in UVA-induced necrotic cell death. The mitochondrial damage leads to 
abrupt interruption of electron chain reactions within the mitochondrial membrane and 
production of ROS as well as depletion of mitochondrial ATP that leads to necrotic cell death 
28 
of UVA-irradiated skin cells. Pretreatment of skin cells with highly lipophilic iron chelators 
SIH, PIH and their caged-photolabile derivative prevented damage to mitochondrial 
membranes, ATP depletion and the ensuing necrotic cell death, as these compounds were 
capable of accessing and sequestering the loosely available LI in these organelles.
26,87 
Similarly Wong et al observed that FRDA fibroblasts treated with DFO were rescued from 
170 
H2O2-induced death to a greater extent than controls. Chelating of intracellular iron with 
the iron chelator DFO has also provided some protection against the formation of H2O2-
171 
induced mitochondrial DNA breaks. Richardson and co-workers have also demonstrated 
that the mitochondria permeable iron chelator 2-pyridylcarboxaldehyde 2-thiophenecarboxyl 
hydrazone (PCTH) was more effective than DFO in preventing the H2O2-induced 
172 
cytotoxicity in cultured FRDA fibroblasts.
The critical role of lysosomal and mitochondrial LI in oxidative injury has also been 
well demonstrated in a series of studies by Lemasters and co-workers showing that 
translocation of LI from lysosomes into mitochondria is a key event during oxidative stress-
induced hepatocellular injury and involves the synergistic action of oxidative stress and LI to 
173 
promote toxic radical formation, mitochondrial dysfunction and cell death.
2.5.5 The role of Nuclear LIP in Oxidant­mediated Iron Damage. The presence of 
high amount of LI in the nucleus is thought to make these organelles highly susceptible to 
23 
oxidative damage. A study from this laboratory has shown that UVA is capable of promoting 
LI-mediated oxidative damage to nuclear membrane of skin fibroblasts leading to a transient 
108 
increase in permeability of the nuclear membrane to proteins. The pre-treatment of 
fibroblasts with iron chelators prevented the UVA-induced destabilisation of nuclear 
108 
membrane. Furthermore it was found that the slow kinetics of induction of Nuclear Factor-
kappa B (NF-kappaB) by UVA relative to other oxidants is due to a transient increase in 
permeability of the nuclear membrane to proteins and occurs as a result of LI-mediated 
108 
damage to nuclear membrane. The apparent slow response of NF-kappaB to UVA 
radiation is likely to have consequences on the kinetics of activation of NF-kappaB target 
genes in the nucleus notably pro-inflammatory cytokines and proto-oncogenes.
108,174 
The nuclear redox-active LI is also thought to be involved in DNA damage induced 
37 
by H2O2 and other oxidising compounds. This assumption is strengthened by studies 
showing a significant correlation between cellular LIP and the yield of 7,8-dihydro-8-
oxoguanine base damage (i.e. a typical marker of ROS-mediated DNA damage) and DNA 
37 
breaks in cells treated with oxidising agents such as H2O2. Furthermore pre-treatment of 
cells with the iron chelator DFO has been shown to prevent the formation of DNA breaks and 
37 
cytotoxicity by H2O2 to nuclear DNA. Interestingly UVA doses that promote a substantial 
increase in cytosolic LIP, have also been shown to induce 7,8-dihydro-8-oxoguanine base 
175 
damage in human skin fibroblasts, a classical marker of oxidised DNA.
3 UVA­Induced Iron­Mediated Damage 
3.1 Mechanisms Underlying the Phenomenon of UVA­induced LI Release 
Fig. 2 summarises potential pathways by which UVA promotes an increase in cytosolic LIP. 
Our research aimed at understanding the source of UVA-induced increase in cytosolic LIP 
has revealed that preventing UVA-induced Ft degradation with specific protease inhibitors 
14 
only partially decreased the observed increase in cytosolic LI following UVA radiation. The 
latter strongly suggested that other sources in addition to Ft’s iron contribute to UVA-induced 
immediate increase in cytosolic LIP. 
Clearly the presence of high level of redox active LI in lysosomes, mitochondria and 
nucleus of skin cells sensitises these organelles to UVA-induced oxidative damage, so it is 
not surprising that exposure of skin cells to UVA at natural exposure levels promotes dose-
dependent damage to these organelles.
28,88,108 
The rapid release of LI from these organelles is 
24 
likely to contribute to the measurable increase in cytosolic LIP which in turn will exacerbate 
the oxidative damage to cell constituents. While the cytosolic LIP is physiologically kept low 
in cells by storage in Ft, the UVA-induced degradation of Ft by lysosomal proteases, further 
contribute to the expansion of cytosolic LIP. The lack of the cytosolic iron storage protein, Ft 
within the critical first hours after irradiation further exacerbates the iron-catalyzed damage in 
irradiated skin cells, since a potentially harmful excess of cytosolic LI can not be safely 
sequestered. Indeed increase in cytosolic LI along with ROS generated by UVA radiation 
promotes further peroxidative damage in exposed skin cells notably in plasma membranes 
and this results in turn in a loss of cell membrane integrity. The latter predisposes the cells to 
necrotic cell death as a result of the influx of extracellular media to the intracellular 
26 
environment leading to swelling and rupture of subcellular compartments and cell lysis.
Concomitant with destabilisation of cell membrane, UVA also promotes an 
immediate depletion in mitochondrial ATP, that is a hallmark of necrotic cell death.
28,87 
The 
UVA-induced mitochondrial ATP depletion is thought to be triggered by several 
simultaneous events. Firstly the presence of a high level of LI in mitochondria may initiate 
the destabilisation of mitochondrial membranes upon UVA treatment as a result of LI-
induced oxidative damage. Secondly the UVA-induced expansion of cytosolic LI by 
lysosomal and nuclear damage as well as Ft degradation may exacerbate the iron-catalysed 
oxidative damage that already occurs in the mitochondrial membrane. Finally the rapid 
release of lysosomal proteases after UVA radiation might further attack the mitochondrial 
membrane leading to additional permeabilisation of the mitochondrial organelles. All these 
events will almost certainly contribute to the observed UVA-induced rapid depletion of 
mitochondrial ATP that leads to the demise of cells in the form of necrosis. Replenishing the 
cellular ATP with glucose led to a substantial decrease in the extent of UVA-induced necrotic 
28 
cell death in skin fibroblasts. Most importantly pre-treatment of skin fibroblasts with iron 
chelators dramatically decreased the level of mitochondrial ATP depletion, plasma membrane 
damage and necrotic cell death.
28,87 
Previous observations from this laboratory have shown that although UVA promotes 
mitochondrial damage and cytochrome c release in fibroblast cell lines such as FEK4, these 
27 
cell lines are particularly resistant to UVA-induced apoptotic cell death. As the presence of 
ATP is essential for the activation of apoptosis protease activating factor-1 (Apaf-1) and 
27
subsequent activation of caspases that induce apoptosis , it appears that the UVA-induced 
25 
immediate depletion of ATP in skin fibroblasts provides a rational explanation for the 
predominance of necrotic cell death induced by UVA. 
In all these damaging processes, LI is clearly involved as pre-treatment of cells with 
both the lysosomotropic iron chelator DFO and the highly lipophilic/cell organelle-permeable 
chelators SIH and PIH fully protected the skin cells against UVA-induced lysosomal, 
mitochondrial and nuclear membrane damage.
28,87,108 
In contrast pre-treatment of skin cells 
with membrane antioxidants such as α-tocopherol succinate (α-Toco), Trolox and butyryl 
hydroxytoluene (BHT) only partially protected the cells against UVA-induced peroxidative 
damage presumably because of the high amount of LI still present in these organelles. Indeed 
the CA-assay revealed that UVA still promotes an increase in LIP in cytosolic compartments 
of cells pre-treated with α-Toco or BHT (unpublished data, this laboratory). Numerous other 
studies in this field have also demonstrated that ‘conventional’ antioxidants have had a very 
modest protective effect, presumably because the investigators have overlooked the 
phenomenon of UVA-induced excess LI release in cells that could still contribute to 
26 
generation of ROS and oxidative damage. Conventional radical scavengers can often not 
neutralise the overall ROS production upon exposure of cells to strong oxidising agents such 
as UVA which also promote redox-active LI release in cells. Because of this dual action, only 
bifunctional antioxidants targeting both LI and ROS have been effective in protecting skin 
cells against UVA-induced oxidative damage and cell death.
26,88,176,177 
UVA not only promotes the early degradation of Ft, but also the degradation of a 
series of hemoproteins notably catalase and microsomal hemoproteins. Microsomal 
hemoproteins are found to be immediately degraded in human skin fibroblasts following 
relatively low doses of UVA with the consequent release of free heme.
15,16 
The UVA-induced 
heme release provides another likely source of LI that may contribute to UVA-induced 
increase in cytosolic LIP, as it has been shown that it can be readily broken down to release 
LI by both the constitutive HO-2 as well as the inducible HO-1 enzymes. The UVA-induced 
heme release has been identified as a key factor in the upregulation of the HO-1 gene in skin 
16 
fibroblasts.
3.2 Mechanisms Underlying the Resistance of Keratinocytes to UVA Radiation 
Compared to skin fibroblasts, skin keratinocytes are more resistant to UVA-mediated 
178 13 
membrane damage and cytotoxicity, although the underlying mechanism is yet to be 
26 
determined. The evaluation of intracellular LIP in a series of matched human primary skin 
fibroblasts and keratinocytes revealed that the basal level concentrations of both cytosolic 
28 
LIP and Ft in keratinocytes is several-fold lower than in fibroblasts. Keratinocytes also 
possess less lysosomal organelles than fibroblasts. The quantification of lysosomal membrane 
damage by neutral red dye uptake assay revealed that the overall UVA-induced damage to 
lysosomal organelles in keratinocytes is also much lower than in skin fibroblasts 
(unpublished data, this laboratory). Moreover, the quantification of lysosomal cysteine 
proteases such as cathepsin-B, -L and -D with ELISA assays revealed that keratinocytes 
possess up to 20-fold lower cathepsin levels than skin fibroblasts. Accordingly following 
UVA irradiation, the level of lysosomal cathepsins delocalised to cytosol was found to be 
much higher in skin fibroblasts than keratinocytes. This was also confirmed by in situ 
detection of cathepsin-B release by epifluorescence microscopy after immunostaining of cells 
with a polyclonal rabbit anti-human cathepsin-B antibody (unpublished data, this laboratory). 
So it appears that although UVA triggers lysosomal damage, Ft degradation and 
cytosolic LI release in keratinocytes, the absolute level of UVA-induced LI release remains 
several-fold lower in these cells than in fibroblasts and this almost certainly contributes to the 
lower level of mitochondrial damage, ATP depletion and necrotic cell death following 
28 
radiation treatment. We propose that a combination of low basal and UVA-induced increase 
in cytosolic LI, low basal level of Ft and low lysosomal organelle and low lysosomal 
cathepsin content will all contribute to the higher resistance of keratinocytes to UVA-induced 
membrane damage and cell death. The level of lactate dehydrogenase release from UVA-
irradiated keratinocytes was found to be 4-fold lower than from UVA-irradiated fibroblasts, 
consistent with the notion that keratinocytes are more resistant to UVA-induced membrane 
damage (unpublished data, this laboratory). Furthermore the UVA dose to give an equivalent 
28 
level of necrosis was found to be several-fold lower in fibroblasts than in keratinocytes. An 
artificial increase in intracellular Ft levels in keratinocytes by overnight treatment of cells 
with hemin or iron-citrate caused a massive increase in cytosolic LI following UVA and a 
strong sensitisation of the cells to very low doses of UVA, implying the importance of 
cytosolic LI concentrations in increased susceptibility of skin cells to UVA-induced oxidative 
damage and cell death.
28,87 
Given that the upper layer of skin (epidermis) receives high levels of UV radiation on 
sunlight exposure, it appears that nature has considerably protected the keratinocytes against 
UVA-induced LI damage. Interestingly in keratinocytes HO-1 is not inducible by UVA, 
27 
however these cells exhibit a high level of constitutive HO-2 protein. In addition to HO-2, 
keratinocytes also possess other strong constitutive antioxidant defense molecules and 
enzymes 
7,52 
that together should be effective in protecting keratinocytes against the 
deleterious effect of UVA-induced oxidative iron damage, as these cells release very low 
28 
amount of cytosolic LI after UVA irradiation.
3.3 The Long Term Effects of UVA­induced LI Release 
The kinetics of LI mobilisation in both fibroblast and keratinocyte cell lines revealed that in 
both cell types, the immediate increase in cytosolic LIP is sustained up to 2 h after irradiation 
and returns to around control value 4-6 h after UVA. The cytosolic LIP remains then 
28 
unchanged as monitored up to 48 h after UVA irradiation. The recovery of cytosolic LIP 
after UVA coincides with the reciprocal de novo synthesis of degraded Ft that occurs within 
the first 2 h after irradiation. The full recovery of Ft content to control levels was observed 
28 
between 4-6 h after irradiation. The kinetics of Ft synthesis after UVA irradiation further 
revealed that the rate of Ft synthesis increases 8-10 h after irradiation and as a result the level 
of cytosolic Ft becomes 2-fold higher 24 h after irradiation when compared to unirradiated 
14 
control cells. This phenomenon was previously thought to occur solely as a result of HO-1 
induction by UVA.
94,95 
However in the light of our recent findings, it appears that the UVA-
induced long-term increase in Ft is a general response of UVA-irradiated cells to UVA-
induced increase in cytosolic LI, where HO-1 also appears to be involved as a potential 
enhancer of cytosolic LI. This argument is strengthened by the observations that pre-
treatment of skin fibroblasts with DFO not only blocked the UVA-induced overnight increase 
in Ft attributed to HO-1 induction
94 
but also the UVA-induced increase in cytosolic LI.
26,28 
3.4 Concluding Remarks 
Overall, our findings demonstrate that UVA-mediated increase in cytosolic LI and heme 
release plays a key role in the increased susceptibility of cells to UVA-induced damage and 
necrotic cell death. Although cells have mechanisms to remove iron (i.e. long-term increase 
in Ft) and heme (HO-1 activation), these defence mechanisms develop over several hours and 
days. Therefore it appears that high intensity short-term exposures to UVA radiation are the 
most likely to be damaging. This is precisely the situation for exposure to sunlamps where 
people tend to expose themselves habitually for short high intensity periods. A clear role for 
28 
iron in exacerbating UVA damage suggests potential pathways for protection through iron 
chelation. However prolonged exposure to strong iron chelators leads to severe side-effects as 
a result of the removal of essential iron from various iron containing proteins, including IRPs 
and hypoxia-inducing factor-1.
26,179,180 
As a result, topical formulations of pro-chelators that 
87 179 
are either activated by UVA light or UVA-induced ROS should provide a safer and more 
26 
efficient alternative for skin photoprotection.
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(Fig. 1: Schematic diagram illustrating the pathways of cytosolic LI uptake and  distribution. 
110 
(Modified from Breuer et al, 2008) . The main source of cytosolic LIP uptake is via receptor-
3+ 
mediated endocytosis (1­3): In extracellular media, transferrin (Tf) binds two atoms of Fe with high 
affinity (1). Two molecules of diferric-Tf bind to the transferrin receptor 1 (TfR1) on the cell surface 
(2). The Tf-TfR1 complex formed is internalized into an endosome. Within the endosome, iron is 
released from Tf following the decrease in intra-vesicular pH (3). Iron transfers from Tf to divalent 
2+ 
metal transporter (DMT1) and is released in the Fe form to the cytosol to join the pool of available 
cytosolic labile iron (LIP) (4). Endosomal iron may be directly delivered to mitochondria (i.e. without 
entering the cytosolic pool) via a hypothetical kiss-and-run mechanism involving DMT1 and 
mitoferrin (Mf) (4A). The cytosolic LIP can be distributed to various cellular targets (5­6): Cytosolic 
LI can be transported by a chaperone (PCBP-1) to be stored in ferritin (Ft) (5). Alternatively cytosolic 
LI may reach and replenish mitochondrial LI either via a hypothetical chaperone or possibly by 
diffusion (5A). Cytosolic LI can also establish a dynamic equilibrium with nuclear LI presumably via 
nuclear pores (5B). Cytosolic LI may also be exported from the cells via ferroportin-1 (FP1) (5C). 
The cytosolic iron stored in Ft may replenish the lysosomal LI via autophagy and proteolytic 
degradation of Ft in lysosomes (6). 
47 
Fig. 2: Schematic diagram illustrating the pathways involved in UVA­induced cytosolic LI release 
and necrotic cell death  in  human  skin  fibroblasts. Exposure of skin fibroblasts to UVA generates 
ROS (orange colour) that promote oxidative damage in lysosomal (1), mitochondrial (2), plasma (3) and 
nuclear (4) membranes. UVA also promotes the immediate degradation of microsomal hemoproteins (5) 
that leads to release of free heme (5B) leading to increase in cytosolic LI via heme oxygenase (HO)-
mediated breakdown of heme (5C­5D). Damage to lysosomal membrane (1) leads to release of 
lysosomal proteases (1A) which in turn degrade the cytosolic iron storage protein ferritin (Ft) and 
release its iron in the labile form (1B). Damage to mitochondrial membrane (2) leads to interruption of 
electron chain transport in mitochondrial membrane causing the generation of ROS, loss of the 
electrochemical gradient across the inner membrane and ATP depletion (2B). The release of potentially 
harmful LI in cytosol via routes (1­5), along with the pre-existing pool of cytosolic LI contribute to a 
massive increase in cytosolic pool of LI (LIP) that catalyses the formation of more harmful ROS (in red) 
that is thought to further exacerbate the peroxidative damage in the lysosomal (1C), mitochondrial (2A), 
plasma (3A) and nuclear (4A) membranes leading to the loss of organelles’ and plasma membrane’s 
integrity. The loss of plasma membrane integrity (3A) together with mitochondrial ATP depletion (2B) 
results in necrotic cell death. 
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